Primary Mediastinal B-Cell Lymphoma
Conditions
Keywords
Primary Mediastinal B-Cell Lymphoma, Positron emission tomography
Brief summary
A non-profit study designed with the aim of analysing the phenotype and molecular characteristics (central review) and evaluating prospectively the role of PET-scans in the management of primary mediastinal lymphoma treated with conventional approaches.
Interventions
None listed
Sponsors
International Extranodal Lymphoma Study Group (IELSG)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary mediastinal diffuse large B-cell lymphoma, CD20 positive. Patients must have histological confirmation of the diagnosis, and in addition have a dominant mass within the anterior mediastinum. * No prior treatment of lymphoma. Patients may have received corticosteroids for up to 1 week for the relief of local compressive symptoms. * Any stage of disease. * Age at least 18 years. * Fit to receive chemotherapy with curative intent. * Able and willing to give informed consent, and to undergo staging including PET scanning * Willingness to comply with an appropriate contraceptive method in women of childbearing potential or men.
Exclusion criteria
* Evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within 12 months before study entry. Cardiac compromise due to local extension of lymphoma will not be an exclusion criterion in the absence of other cardiac disease. * Impairment of bone marrow function (WBC \<3.0x109/L, ANC \<1.5x109/L, PLT \<100x109/L), unless due to involvement by lymphoma. * Major impairment of renal function (serum creatinine \>2x upper normal) or liver function (ASAT/ALAT \>2,5 upper normal, total bilirubin \>2,5x upper normal), unless due to lymphoma involvement. * Known HIV infection. Patients will not be tested routinely. * Pregnant or lactating women. * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate on PET scanning following initial chemo-immunotherapy | — |
Countries
Italy, Spain, Switzerland, United Kingdom
Outcome results
None listed